A New Patient-Built Questionnaire Could Change How IBM Trials Measure Success
When a clinical trial says a treatment helped, what does that really mean? For decades, IBM trials have leaned heavily on strength tests and walking tests. But anyone living with IBM knows the disease affects far more than strength — fatigue, pain, swallowing, speech, and independence all matter enormously. A tool published in June 2026 in the Journal of Clinical Neuromuscular Disease aims to make sure those things finally get measured.
What the Researchers Did
Researchers at the University of Rochester conducted one of the largest patient-survey efforts ever done in IBM. They asked 569 people living with IBM which symptoms are most prevalent and most impactful in everyday life, then used those answers to build a questionnaire called the IBM-HI (Inclusion Body Myositis-Health Index). The tool was refined with beta testers and validated for reliability: 21 participants completed it twice, two weeks apart, with highly consistent scores.
The result is a 97-item questionnaire covering 13 areas of life — including mobility, fatigue, pain, swallowing, speech, and emotional well-being — that takes about 11 minutes to complete.
Why It Matters
A scale is only useful if it can tell the difference between people doing better and worse — and the IBM-HI can. It reliably distinguished between groups expected to differ in disease burden: people with more versus less disability, longer versus shorter disease duration, those receiving disability benefits, and those who can versus cannot walk independently.
The IBM-HI was built to meet FDA standards for use in clinical trials and regulatory claims, which means drug developers could use it to support treatment-approval decisions. It is already being used in INSPIRE-IBM, an NIH-funded observational study.
What This Means for IBM Patients
This represents a quiet but important shift in how the field will judge new treatments — not only "did muscle strength hold steady?" but "did the things that matter to you — energy, swallowing, independence — stay stable or improve?" Patient input shaped every question on the tool, so the voice of the IBM community is now built into how future treatments will be evaluated.
It is worth pausing on that: 569 people took the time to describe their daily reality with IBM so that future trials would measure the right things. That effort now sits at the center of how new treatments will be judged.
Source
• Irwin C, Rosero S, Seabury J, et al. "Development and Validation of the Inclusion Body Myositis-Health Index: A Disease-Specific Patient-Reported Outcome Measure." Journal of Clinical Neuromuscular Disease. 2026 Jun 1;27(4):124-139. doi: 10.1097/CND.0000000000000564.
Tags
Related Reading
- Early Stage Tips — Exercise, energy conservation, and specialist directories
- Bathroom & Toileting — Equipment, bidets, and transfer techniques
- Travel Tips — Airlines, hotels, and emergency preparedness
- General Tips — Insurance, disability benefits, and support groups